Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Sanofi Signs Agreement to Acquire Colombian Pharmaceutical Company, Genfar

By BiotechDaily International staff writers
Posted on 15 Oct 2012
The French pharmaceutical giant Sanofi (Paris, France signed of a definitive agreement to acquire Genfar SA (Bogota, Colombia).

With this deal signed on October 2, 2012, Sanofi will become a market leader in Colombia and expand its range of cost-effective pharmaceutical agents in Latin America, according to GlobalData (London, UK), an international market research firm. GlobalData believes the race by pharmaceutical companies to establish themselves in the CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) countries might just have begun. With companies such as Eli Lilly and Pfizer already responding to analysts’ calls for prudence about the potential of emerging markets by reducing their forecasts, the CIVETS countries, which are regarded as second-generation emerging markets and holding significant potential, seem to be the next big thing.

Sanofi’s acquisition is one that could generate significant dividends to the company in the future. In an incredibly competitive global pharmaceutical market, the one who moves first can take advantage, which can frequently be a key determinant of success or failure for players in specific geographic markets. As a result, Sanofi could potentially establish itself as a powerhouse with in Colombia and strengthen the barriers to entry for other pharmaceutical companies that may decide to later enter--meaning, according to GlobalData spokespersons, “get in, bolt the door, and lose the key.” Moreover, the company could utilize its entry into Colombia as a starting point for penetrating other CIVETS countries.

Moreover, Sanofi could potentially achieve comparative advantage over its competitors by moving most of its labor-intensive processes to Colombia, and subsequently other second-generation emerging markets. The cost of labor is expected to be significantly lower in these markets than in first-generation emerging markets including China, India, and Brazil. Therefore, by moving into fruitful economies outside of emerging markets, which are destined to become overcrowded at some time because of the swift movement of pharmaceutical companies into them, Sanofi would enjoy reduced costs and consequently, be able to compete on price if the need arises.

According to GlobablData, by acquiring Genfar, Sanofi is jumping into second-generation emerging markets. It will be interesting to see what the pharmaceutical giant will do next.

Related Links:

Sanofi
Genfar
GlobalData



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.